Minimal Residual Disease and Hematologic Malignancies

Slides:

Advertisements

Similar presentations

Minimal Residual Disease in Hematologic Neoplasms Lloyd M. Stoolman, M.D. Professor of Pathology and Director, Clinical and Research Flow Cytometry Laboratories.

Advertisements

Adult ALL – therapeutic strategies, including Burkitt

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.

Approach to leucocytosis Jackie Thomson.

Questions to the Committee. Question 1. The Agency has accepted durable responses in hematologic malignancies for approval for both chronic leukemias.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Acute Leukemia Kristine Krafts, M.D..

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genome-wide Interrogation of Germline Genetic Variation.

Acute Leukemia Kristine Krafts, M.D..

19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL

Multimodal Management of Opioid-Induced Constipation

Upfront Combination Therapy vs Step-Up Approach for PAH:

Clinically useful prognostic factors in acute myeloid leukemia

Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.

Supplemental table 1 Patients' characteristics Variables Number

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.

The Role of MRD in Hematologic Malignancies

The Role of MRD in Hematologic Malignancies

Gupta V, Tallman MS, Weisdorf DJ

Monitoring and Prevention of Relapse after Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies Ulrike Bacher, Julie-An Talano, Michael.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Acute leukemia: A pediatric perspective

Treating Transplant-Ineligible Patients With Multiple Myeloma

Goals of Therapy in Relapsed CLL

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Advances in Myeloid Malignancies

How Can we Improve Outcomes for the Elderly Patient with AML?

Counseling Patients About Germline BRCA Mutations

Clinical Implications of Clonal Hematopoiesis

Management Challenges in CLL

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

Adrian G. Selim, Andrew S. Moore The Journal of Molecular Diagnostics

Advances in Multiple Myeloma

Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric.

Detecting and Treating Asparaginase-Related Toxicities in Acute Lymphoblastic Leukemia.

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Minimal Residual Disease in CLL

Approaches in Newly Diagnosed Multiple Myeloma: When and What

Staying Abreast of Best Practices Across the Clinical Continuum

Managing Multiple Myeloma in the Elderly

Chronic Myeloid Leukemia

CALL FOR ABSTRACTS Saturday, November 3,2018

Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis

The Role of IDH Inhibitors in Hematologic Malignancies

Managing Age-Related Clinical Issues in Hemophilia

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

New ELN Recommendations

An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Assessing the Burden of Hyperkalemia

The Role of Measurable Residual Disease in AML

Disease Burden of VTE Phases of VTE Treatment.

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Assessing the Burden of Hyperkalemia

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients Mithun Vinod Shah, Rima M.

PAH Pathways: What Do the Data Tell Us?”

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Clinical Lymphoma, Myeloma and Leukemia

MRD Analysis in Chronic Lymphocytic Leukemia

The Building Blocks of Homocystinuria and Homocysteinemia Management

Timing for HCT Consultation

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Transplants Facilitated by NMDP/Be The Match

What's New in Rare CKDs?.

Supplementary Table 1. TTI-621 binds to human tumor cell lines

Utilizing MRD Assessment in Community Practice

Presentation transcript:

Minimal Residual Disease and Hematologic Malignancies

Contents

MRD in Multiple Myeloma

Rationale for Measuring MRD in MM

Methods and Results

Implications for Clinical Practice

Emerging Approaches to Assess MRD

MRD in Acute Lymphoblastic Leukemia

MRD in ALL

MRD in ALL (cont)

MRD in Acute Myeloid Leukemia

Why Assess MRD in Patients With AML?

Methods of Assessing MRD in AML

What Prognostic Information Can MRD Potentially Provide?

Challenges and Questions

MRD in Chronic Lymphoblastic Leukemia

Testing Methods

Implications

Abbreviations

Abbreviations (cont)